Novartis

Global Peptide Synthesis Market Report 2024, with Revenue Data from 2020-2023, Forecasts and CAGRs Projections for 2024-2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 23, 2024
Biotechnology, Pharmaceutical, Health, Novartis, Teva Pharmaceuticals, Intelligence, AbbVie, GCC, ESG, Peptide, Lilly, AstraZeneca, Fine chemical

For each of these areas, current products in the market are identified, measuring the market size and identifying potential market drivers.

Key Points: 
  • For each of these areas, current products in the market are identified, measuring the market size and identifying potential market drivers.
  • Forecasts for 2028 are attained by analyzing the current competitors' market shares for the base year of 2022.
  • By geographic region, the market is segmented into North America, Europe, Asia-Pacific and the Rest of World.
  • For market estimates, data is provided for 2022 as the base year, with estimates for 2023 and forecast values for 2028.

United States Pet Medication Market Insights Report 2024-2029 Featuring Prominent Vendors - Boehringer Ingelheim, Ceva, Elanco Animal Health, Merck, Zoetis, Bayer AG, and Novartis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 17, 2024
Pharmaceutical, Health, Veterinary, USD, Vaccination, Inflammation, Bayer, Nonsteroidal anti-inflammatory drug, Boehringer Ingelheim, Pet, Parasitism, Animal, Insurance, Zoonosis, Urbanization, Tick, Prescription, Cat, Human, Novartis, Family, Pain management, Food, Anesthetic, Dog, Merck, Growth, Prevalence, Medical imaging

The U.S. pet medication market report contains exclusive data on 39 vendors.

Key Points: 
  • The U.S. pet medication market report contains exclusive data on 39 vendors.
  • The competition in the U.S. pet medication market is intense, with several global players offering diverse products.
  • Currently, Ceva, Zoetis, Boehringer Ingelheim, Merck, Elanco, Bayer AG, and Novartis are the leading vendors in pet medication production and distribution in the U.S.
  • The prescription medications segment occupies a significant market share of over 53% in the U.S. pet medication market.

QuantHealth Appoints Esteemed Pharmaceutical Executives to Inaugural Advisory Board

Retrieved on: 
Tuesday, April 16, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Artificial Intelligence, Other Science, Research, Software, General Health, Health Technology, Science, Data Management, Clinical Trials, AbbVie, Innovation, MD, Entrepreneurship, Novartis, Data, Patient, Digital transformation, Former, Drug development, Clinical trial, Pharmaceutical industry

QuantHealth , an AI-powered clinical trial design company, today announced the formation of its inaugural Advisory Board.

Key Points: 
  • QuantHealth , an AI-powered clinical trial design company, today announced the formation of its inaugural Advisory Board.
  • The board members will help support the development and deployment of the company’s core platform services to propel the greater life sciences sector forward.
  • QuantHealth envisions a world where clinical trial simulations and synthetic trials are an integral part of every trial's design process and regulatory path.
  • The assembly of this advisory board underscores the company’s commitment to addressing the changing needs and challenges of the industry by democratizing data to fuel clinical trial development at-large.

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics

Retrieved on: 
Tuesday, April 16, 2024
Technology, Biotechnology, FDA, Nanotechnology, Health, Pharmaceutical, Stem Cells, Other Science, Research, Infectious Diseases, Genetics, Fitness & Nutrition, Science, Clinical Trials, CTA, CRISPR, PMM, OTC, Gene editing, Partnership, Doctor of Philosophy, DMD, Prevail, Webcast, IND, Entrepreneurship, Novartis, DNA, Precision BioSciences, GLP, Eli Lilly and Company, CTAS, Toxicology, ID, Therapy, Precision, HBV, Vaccine

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company.
  • Precision exercised its option to regain rights for the programs following Prevail Therapeutics’ decision to conclude the collaboration.
  • The collaboration began in January 2021 and was amended in June 2023 to transfer certain preclinical research, manufacturing, and investigational new drug (IND)-enabling activities from Precision BioSciences to Prevail Therapeutics.
  • “We enjoyed a productive gene editing collaboration with Prevail Therapeutics and appreciate their contributions to the success of these programs.

MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis

Retrieved on: 
Thursday, April 11, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Cancer, EDT, MorphoSys, Takeover, ADS, Novartis, Patient, Supervisory board, Acquisition

The Management Board and Supervisory Board of MorphoSys AG (FSE: MOR; NASDAQ: MOR) today issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG (hereinafter collectively referred to as “Novartis”), recommending that shareholders accept the offer and tender their MorphoSys shares.

Key Points: 
  • The Management Board and Supervisory Board of MorphoSys AG (FSE: MOR; NASDAQ: MOR) today issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG (hereinafter collectively referred to as “Novartis”), recommending that shareholders accept the offer and tender their MorphoSys shares.
  • Novartis offers MorphoSys shareholders € 68.00 per share in cash, representing a total equity value of € 2.7 billion (the “Takeover Offer”).
  • “The offer made by Novartis provides MorphoSys shareholders with an opportunity to realize significant value upfront and with certainty.
  • The MorphoSys Management Board and Supervisory Board joint reasoned statement, as well as other relevant information for shareholders, is available on the MorphoSys website at https://www.morphosys.com/en/investors/Novartis-TakeoverOffer .

STALICLA Appoints Dr. Thomas Blaettler, MD

Retrieved on: 
Thursday, April 11, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Health Technology, FDA, Shirin David, University, Central nervous system disease, PNAS, Neuroscience, Maas, Neurodevelopmental disorder, Phase II, CNS, Roche, CFDA, Novartis, Science, Patient, EMA, Initial public offering, Multimedia, BMS, Drug development, Medicine, PMDA, Myenteric plexus, Pharmaceutical industry

STALICLA SA, a Swiss clinical-stage biotechnology company focused on advancing precision medicine for brain diseases, announced today the appointment of Thomas Blaettler, to the position of Chief Medical Officer.

Key Points: 
  • STALICLA SA, a Swiss clinical-stage biotechnology company focused on advancing precision medicine for brain diseases, announced today the appointment of Thomas Blaettler, to the position of Chief Medical Officer.
  • View the full release here: https://www.businesswire.com/news/home/20240411118139/en/
    Thomas Blaettler, MD, joins STALICLA as Chief Medical Officer.
  • (Photo: Business Wire)
    Dr. Thomas Blaettler brings a wealth of pharmaceutical development experience and deep insights to help progress STALICLA’s ambitions in CNS conditions.
  • Thomas has profound regulatory experience across the globe (EMA, FDA, PMDA, CFDA) from pre-IND interaction to submissions of NDAs and MAAs.

Gordian Biotechnology Introduces High-Throughput In Vivo Screening Platform to Discover Therapies and Better Predict Human Outcomes for Age-Related Diseases

Retrieved on: 
Friday, April 26, 2024
Founders Fund, FDA, OA, Patient, Horse, Cell, Notifiable disease, Animal, OARSI, Osteoarthritis Research Society International, Infection, Entrepreneurship, Research, Pathology, Artificial intelligence, Disease, Human, Novartis, Therapy, Ageing, Pulmonary fibrosis, Osteoarthritis, Gene, Biology, Drug discovery, Longevity, World Congress, MASH, Heart failure, Pharmaceutical industry

SAN FRANCISCO, April 26, 2024 /PRNewswire/ -- Gordian Biotechnology, an in vivo drug discovery and development company, today announced its platform that enables patient predictive, in vivo screening of hundreds of gene targets for FDA-recognized diseases of aging at a scale never before possible.

Key Points: 
  • Gordian's Osteoarthritis (OA) program has screened hundreds of therapies in horses that acquired OA naturally and advanced dozens of therapies into human ex vivo validation studies.
  • In proof of concept experiments during initial development, Gordian introduced a pooled library of 50 gene therapies into a mouse model of metabolic-associated steatohepatitis (MASH).
  • The therapies were evaluated using the company's proprietary in vivo screening platform, which successfully recapitulated 13 out of 16 clinical outcomes for targets where clinical data exists.
  • Mosaic Screening™ is pooled in vivo screening that tests hundreds of therapies simultaneously in a single sick animal, the Patient Avatar.

The Multiple Sclerosis Association of America Proudly Announces the 10th Improving Lives Benefit in Support of the MS Community

Retrieved on: 
Thursday, April 18, 2024
MSAA, NFL, Engagement, Dream, Foundation (nonprofit), Research, Hall, Novartis, Clinical trial, Multiple sclerosis, Barnes Foundation, Pharmaceutical industry

CHERRY HILL, N.J., April 18, 2024 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) is excited to invite members of the MS community to our 10th Improving Lives Benefit on Wednesday, May 15, 2024, at 6:30 pm ET, at the Barnes Foundation in Philadelphia, PA. This event will also be livestreamed, allowing individuals from across the country to participate from the comfort of their homes. Those attending will have the opportunity to connect with inspiring individuals, recognize our special honorees, and support MSAA's programs and services that are provided at no cost to the MS community.

Key Points: 
  • MSAA is very pleased to announce the return of our previous Improving Lives Benefit host, Tyler Campbell.
  • In this latter role, Dr. Hendin provides vital guidance on many of MSAA's initiatives – all with the goal of Improving Lives Today for the MS community.
  • "We are thrilled to recognize our two special honorees at this year's Improving Lives Benefit," says Gina Ross Murdoch, MSAA President and CEO.
  • For more information regarding MSAA's 10th Improving Lives Benefit, please contact Diana Cruz, Manager of Public Relations & Engagement, at (800) 532-7667, ext.

Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

Retrieved on: 
Wednesday, April 17, 2024
USD, Urine, ACE, Finerenone, ESRD, Kidney, Otorhinolaryngology, Nephrotoxicity, Mutation, Hearing, Diagnosis, Glomerular filtration rate, Hearing loss, Blood, Swelling, Proteinuria, Kidney failure, Cochlea, Alport syndrome, Nephrology, EU4, GFR, ADAS, Heredity, Research, Genetic counseling, Kidney disease, Novartis, ARAS, Ophthalmology, COL4A4, Patient, Kidney transplantation, LAS, Dialysis, DSM-IV codes, COL4A3, Quality of life, Genetic disorder, Gene, Pharmaceutical industry

LAS VEGAS, April 17, 2024 /PRNewswire/ -- DelveInsight's Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Points: 
  • Leading Alport syndrome companies such as Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec, and others are developing novel Alport syndrome drugs that can be available in the Alport syndrome market in the coming years.
  • The disorder manifests in different forms such as autosomal recessive Alport syndrome (ARAS), X-linked Alport syndrome (XLAS), and autosomal dominant Alport syndrome (ADAS).
  • The X-linked Alport syndrome (XLAS) is the most prevalent subtype of Alport syndrome with around 11K cases in 2023 in the US while autosomal dominant Alport syndrome (ADAS) is the least prevalent subtype of Alport syndrome.
  • To know more about Alport syndrome treatment guidelines, visit @ Alport Syndrome Management

Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

Retrieved on: 
Wednesday, April 17, 2024
USD, Urine, ACE, Finerenone, ESRD, Kidney, Otorhinolaryngology, Nephrotoxicity, Mutation, Hearing, Diagnosis, Glomerular filtration rate, Hearing loss, Blood, Swelling, Proteinuria, Kidney failure, Cochlea, Alport syndrome, Nephrology, EU4, GFR, ADAS, Heredity, Research, Genetic counseling, Kidney disease, Novartis, ARAS, Ophthalmology, COL4A4, Patient, Kidney transplantation, LAS, Dialysis, DSM-IV codes, COL4A3, Quality of life, Genetic disorder, Gene, Pharmaceutical industry

LAS VEGAS, April 17, 2024 /PRNewswire/ -- DelveInsight's Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Points: 
  • Leading Alport syndrome companies such as Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec, and others are developing novel Alport syndrome drugs that can be available in the Alport syndrome market in the coming years.
  • The disorder manifests in different forms such as autosomal recessive Alport syndrome (ARAS), X-linked Alport syndrome (XLAS), and autosomal dominant Alport syndrome (ADAS).
  • The X-linked Alport syndrome (XLAS) is the most prevalent subtype of Alport syndrome with around 11K cases in 2023 in the US while autosomal dominant Alport syndrome (ADAS) is the least prevalent subtype of Alport syndrome.
  • To know more about Alport syndrome treatment guidelines, visit @ Alport Syndrome Management